Browse studies

Find your next paid study

4,613 recruiting studies matching your filters

Detection and Characterization of Host Defense Defects

This protocol is designed to evaluate selected patients with documented recurrent or unusual infections and their family members for clinical and laboratory co…

Immune Defects

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT00001355

Phase 1

A Phase 1, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-7828, and to Evaluate the Effect of Food on ABBV-7828 Pharmacokinetics in Healthy Adult Subjects

This study is to evaluate safety, tolerability, pharmacokinetics and effect of food on ABBV-7828 compared to placebo in healthy adult participants.

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6103, a Novel FAP-activated Exatecan Administered Intravenously in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients …

Vulvar AdenocarcinomaPDAC - Pancreatic Ductal AdenocarcinomaGastric Adenocarcinoma+6 more

Estimated

~$10 – $8,750

Avacta Life Sciences LtdNCT07454642

Observational

GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study

A prospective multi-center post-market study collecting outcomes through at least 5-years and up to 10-years post procedure for subjects treated with the TBE D…

Aortic Arch DissectionAortic Arch Aneurysm

Estimated

~$10 – $7,500

W.L.Gore & AssociatesNCT07166133

Phase 1

DCE-MRI-Informed Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

This clinical trial tests how well dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with standard clinical evaluation works to assess treatment r…

Borderline Resectable Pancreatic Ductal Adenocarcinoma

Estimated

~$10 – $6,250

Ohio State University Comprehensive Cancer CenterNCT07705919

Phase 2

A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma

The goal of this clinical research study is to learn if zanzalintinib can help to control recurrent/metastatic ONB. The safety of zanzalintinib will also be st…

Metastatic Olfactory Neuroblastoma

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07527169

Phase 2

A Phase 2, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases

The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE)…

Systemic Lupus ErythematosusActive Refractory Rheumatoid Arthritis

Study Assessing the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

This study is designed to demonstrate the efficacy and assess safety and tolerability of oral daily alpelisib in participants with PIK3CA-related overgrowth sp…

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT06997588

Phase 3

A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Pancreatic CancerPancreatic Cancer MetastaticPDAC+5 more

Estimated

~$10 – $8,750

Immuneering CorporationNCT07562152

Characterizing SARS-CoV-2 Persistence in Host Reservoirs, Post-viral Sequelae, and Associations With Host and Viral Determinants in a Cohort of Convalescent COVID-19 Cases

The 2019-2020 COVID-19 pandemic is the largest outbreak in recent history. It is not known how long after someone gets sick with COVID-19 and recovers that the…

COVID-19Corona Virus InfectionSARS-CoV 2

Estimated

~$10 – $750

Columbia UniversityNCT04448145

Phase 2

An Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

Background: Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, …

SuicideDepressive Disorder, Treatment-ResistantKetamine+10 more

Estimated

~$10 – $5,625

National Institute of Mental Health (NIMH)NCT06511908

Phase 1

Channeling Hope Trial 1: A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) of Chronic Aprepitant Use in Individuals With Congenital Contractures of the Limbs and Face, Hypotonia, and Development Delay (CLIFAHDD)

There are no drug treatments for individuals with Congenital Contractures of the Limb and Face, Hypotonia, and Developmental Delay (CLIFAHDD), an ultra-rare an…

CLIFAHDDCongenital Contractures of the Limbs and Face, Hypotonia, and Developmental DelayNALCN Channelopathy+2 more

Estimated

~$10 – $6,250

The University of Texas Health Science Center at San AntonioNCT07845825